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Use of reliable contraceptives 
and its correlates among women 
participating in Simulated 
HIV vaccine efficacy trials in 
key-populations in Uganda
Abaasa1,2*, Jim todd2, Yunia Mayanja1, Matt price3,4, Patricia E. fast3,5, Pontiano Kaleebu1 & 
Stephen nash  2
To prevent pregnancy in trials, reliable contraceptive use is key. We investigated reliable contraceptive 
use at baseline and six months in key-populations in Uganda, during two Simulated HIV Vaccine Efficacy 
trials (SiVETs). SiVETs were nested within observational cohorts of Fisherfolk (2012–2014) and Female 
sex workers (2014–2017). Women in the observational cohorts were screened and enrolled into the 
SiVET. The trial administered a licensed Hepatitis B vaccine at 0, 1 and 6 months. Contraceptive use 
data were recorded at baseline and follow-up clinic visits. Reliable contraceptives (injectable Depot 
Medroxyprogesterone Acetate (DMPA), implant, pills, and intrauterine device (IUD)) were promoted 
and provided to women not using a reliable method at enrolment. Overall, 367 women were enrolled. 
At baseline 203 (55%) reported use of reliable contraceptive. Of the 164 women not using a reliable 
method at enrolment, 131 (80%) started using them during follow-up bringing the overall number to 
334 (91%) at the end of follow-up. Young age (≤35 years) was an independent predictor of reliable 
contraceptive use at both time points while other factors varied. Promotion and provision of reliable 
contraceptives increased the proportion using them and could help reduce the risk of pregnancy in 
future HIV prevention trials.
Sub-Saharan Africa (SSA) suffers the highest burden of HIV with 70% of the people living with HIV in 2017 
being residents in SSA1. Similarly, global estimates show that 65% of new HIV infections in 2017 happened in 
this region1. Some sub-populations, such as members of fishing communities (fisherfolks-FF) and female sex 
workers (FSW), are disproportionately affected. The HIV prevalence in fishing communities is as high as 37%2–6 
and annual HIV incidence of more than 3 per 100 person years have been reported7,8. The HIV burden is worse 
among women2,4. Because of the high HIV incidence, these communities are attractive for the conduct of HIV 
vaccine efficacy trials. However, trials could take months or years from recruitment to completion. In this long 
period, women could become pregnant and might have to be withdrawn from follow up due to unknown effects 
of the new investigational product on the fetus. More withdrawals than that anticipated could have negative 
effects on the trial statistical power9–11. In such efficacy trials, it is important to prevent pregnancies in women 
participants through the use of reliable, long-acting, reversible contraceptive methods.
Reliable contraceptives defined as non-barrier methods likely to reduce the risk of pregnancy include injecta-
ble Depot medroxyprogesterone acetate (DMPA), pills, Norplant-implant and intrauterine contraceptive device 
(IUCD)12. The use of reliable contraceptives in women of reproductive age is low, at 64% globally, 28% in SSA and 
40% in East Africa13. Lack of access to and concerns regarding side effects or health risks associated with contra-
ceptives use have been the main reasons advanced for the low use in SSA14. In Uganda, 35% of women in the gen-
eral population use reliable contraceptives, although this may be higher in specific sub-groups of the population15.
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Previous HIV prevention trials in non-fishing communities in Africa (East, West and Southern Africa) have 
shown that reliable contraceptive use is low, ranging between 5% to 28%12,16–19. In a 2013 review of microbicide 
trials in Africa the incidence of pregnancy ranged from 4.0 to 64 per 100 women-years20. There is little data on 
uptake of reliable contraception and the impact of contraception on pregnancy during these trials.
High levels of willingness (>95%) to participate in HIV vaccine efficacy trials have been shown in Africa21,22. 
However, among women this decreased to 23% when the need to prevent or delay pregnancy through use of 
reliable contraceptives was mentioned21. To date, no HIV vaccine efficacy trials have been conducted in women 
at high-risk of HIV infection in Uganda, and there is no baseline information on the use of reliable contraceptive 
methods to delay pregnancy during HIV prevention trials. It is unknown how the use of reliable contraceptives 
and risk of pregnancy would change among study participants and how this would affect HIV vaccine efficacy 
trials in these populations.
In populations where no baseline data on reliable contraceptives use is available, prospective trial participants 
may be required to use reliable contraceptive methods for at least three months before screening and enrol-
ment23. This increases the cost of conducting trials and delays rollout, but avoids costly drop out from trials due to 
non-compliance. Studies aimed at establishing factors associated with reliable contraceptives use under efficacy 
trial conditions, can provide baseline data to be used in planning such trials in the FF and FSW populations where 
little or no information is available.
Recently, we conducted two “Simulated HIV Vaccine Efficacy Trials (SiVETs)” in which procedures and cri-
teria for the trial mimicked an HIV vaccine efficacy trial, but the vaccine used was a licensed Hepatitis B vaccine. 
Participants were informed that this trial was a simulation and the vaccine would protect them against Hepatitis 
B, not HIV. The SiVET concept is suggested to be useful in assessing the feasibility for conduct of clinical trials of 
a new product, through a “simulated” trial using a commercially available vaccine24,25. This concept can inform 
the design and sample size estimation for the future trials26–28.
In this paper, we use data from the two SiVETs, in which reliable contraceptives were promoted and provided 
at no cost to female participants, to: determine the proportion of women using a reliable method (i) at baseline 
and (ii) at the end of vaccination schedule (6 months of follow up), and to determine the correlates of reliable 
contraceptives use (iii) at baseline and (iv) at 6 months of follow up.
Methods
The data for this paper come from two Simulated HIV Vaccine Efficacy Trials (SiVETs) in Uganda. To assess 
and improve readiness for efficacy trials of HIV preventive vaccines or other investigational agents among key 
populations in Uganda, we conducted two trials in which licensed Hepatitis B vaccine was used in a protocol 
that otherwise resembled an efficacy trial for HIV vaccine. These were nested in, respectively, an observational 
cohort of FF (Jul 2012–Apr 2014) in Masaka and a cohort of FSW (Aug 2014–Apr 2017) in Kampala. Both studies 
were conducted by MRC/UVRI & LSHTM Uganda Research Unit clinics supported by the International AIDS 
Vaccine Initiative (IAVI). The observational cohorts details have been previously described6,8,29,30. Sexually active 
(self-reported having sex in the preceding three months) HIV negative women who had been part of the observa-
tional cohorts’ quarterly follow up (aimed at determining HIV incidence) for between three and 18 months were 
screened for eligibility (Table 1) for enrollment into the SiVET. Those eligible were asked if they were using any 
method of contraceptive. The contraceptive methods were classified as either reliable (injectable DMPA, implant, 
oral pills, and IUD), or unreliable (condoms, lactational amenorrhea, withdrawal etc.). The study nurse promoted 
reliable contraceptives to women who were not using any method, or were using an unreliable method, at base-
line. Eligible women who were either already using a reliable method or were willing to initiate one were enrolled 
into the SiVET. They were provided with a reliable contraceptive method of their choice. While DMPA and oral 
pills were provided at both study site clinics (Kampala and Masaka), implant and IUD were provided by the study 
staff only at the Kampala clinic. At the Masaka clinic, women were referred to a Marie Stopes clinic located about 
one kilometre from the study research site clinic where they could obtain implant or IUD.
All enrolled women were provided with a contraceptive card, which captured the method they were using 
and any future changes or renewals. They were requested to carry their card every time they visited the study 
research clinic. Contraceptive use data was collected at enrolment, and at months one, three, and six. At enrol-
ment, women were administered a licensed Hepatitis B vaccine (ENGERIX-BTMGlaxoSmithKline Biologicals 
Eligible Ineligible
• At least 3 and no more than 18 months of follow up in the observational cohort • HIV-1 infection
• HIV-1 negative and willing to undergo HIV testing • Pregnant or intending to get pregnant
• Aged ≥18 years and ≤49 years •  Previous exposure to Hepatitis B or current infection (only Kampala clinic)
• Able and willing to provide informed consent • History of severe allergic reaction to any substance
• Able and willing to provide adequate locator information • An acute or chronic illness
• Willing and able to return for follow-up clinic visits • Contraindication for Hepatitis B vaccine
• Intending to reside in the study area for at least one year • Participation in another clinical trial
• Willing to undergo pregnancy testing
• Not breastfeeding and no intent for pregnancy in the next year
• Willing to use a reliable method of contraceptives during the study
Table 1. Eligibility Criteria for screening/enrolment into SiVET at Kampala & Masaka clinics, Uganda.
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Rixensart, Belgium) following the standard schedule of 0, 1 and 6 months, akin to what might happen in an HIV 
vaccine efficacy trial. After each vaccination, women were retained in the clinic for at least 30 minutes for reacto-
genicity events assessment. Furthermore, they were requested to return after three days for further review. Details 
of the trial procedures and follow up have been previously described31,32.
Pregnancy testing: Women were asked to provide a urine sample at each clinic visit for pregnancy testing. A 
QuickVue One-Step human chorionic gonadotropin (HCG) test (manufacturer: Quidel Q20109IN) was used to 
determine pregnancy.
Statistical analysis. SiVET data were captured using OpenClinica 3.5 (Waltham, MA). The data were 
transferred to Stata 14 (StataCorp, College Station, TX USA) for cleaning and analysis. Variables examined 
included; social demographics- age, tribe, education, religion, marital status, occupation and duration of resi-
dency. Behavioral - frequency of alcohol consumption, having sex under the influence of alcohol, illicit drug use, 
number of sexual partners, having a new sexual partner other than the regular partner, frequency of condom use 
with a new sexual partner and being away from home for at least 3 days per week. Clinical – having had a genital 
discharge and/or genital sores/ulcer disease in the three months preceding the interview. Participant baseline 
socio-demographic, study site, HIV risk behavior, and clinical characteristics were summarized using counts and 
percentages and further stratified by study population and whether or not a participant reported use of a reliable 
contraceptive method at enrolment. Similarly, participant characteristics were compared between those who took 
up a reliable contraceptive method and those who did not. The numbers of women who took up a reliable con-
traceptive method overall, and at each clinic visit, were presented using a bar graph. We defined uptake of reliable 
contraceptives as a woman using an unreliable or no method at enrolment into SiVET but taking up one of the 
reliable methods at any one point during follow up. Simple logistic regression models were fitted to determine 
correlates of reliable contraceptives use at baseline and at the last vaccination visit (six months of follow up). After 
bivariable analyses, a multivariable model was fitted. In the multivariable model, factors were removed from the 
model using a backward elimination algorithm retaining any factors, which caused a change in the log odds of 
20% or more.
Results
Screening. In total, 464 [FF = 83 and FSW = 381] sexually active women were screened for entry into the 
SiVETs, of whom 367 (79%; FF = 77 (93%) and FSW = 290 (76%)) non-pregnant women were enrolled, over-
all screening-enrolment ratio of 5:4. Of the 97 women ineligible for enrolment, the primary reason was prior 
exposure to Hepatitis B (54%, n = 52). Eight women (8%) were excluded because of pregnancy; other reasons for 
exclusion are shown in Fig. 1.
Baseline characteristics. In the FF population, the average age of enrolled women was 30 years (SD = 7.5, 
range 18–49), with 38 (49%) being of the indigenous Baganda tribe, 57 (74%) of Christian faith, 49 (64%) had pri-
mary education and 54 (70%) had lived at the current location for more than one year. All participants reported 
having a new sexual partner (not a regular sexual partner) in the three months preceding the interview and 47 
(61%) reported never using a condom while having sex with the new sexual partner (Table 2). In the FSW pop-
ulation, the average age was 28 years (SD = 7.5, range 18–49), with 153 (53%) being of the indigenous Baganda 
tribe, 219 (76%) of Christian faith, 149 (51%) had primary education, 204 (70%) single but previously married. 
Two hundred and thirty nine (82%) had lived at the current location for more than one year. A total of 235 (81%) 
reported illicit drug use, 287 (99%) reported two or more sexual partners, 266 (92%) reported having a new sexual 
partner in the 3 months preceding the interview and 207 (78%) reported that they always use a condom while 
having sex with a new sexual partner (Table 2).
Baseline contraceptives use (Table 2). Of the 367 women enrolled, 213 (58%; FF = 30 (39%) and 
FSW = 183 (63%)) reported use of some form of contraceptive at baseline. Reliable methods were used by 203 
women (55%; FF = 24 (31%) and FSW = 179 (62%)) which included 136 (67%) women using injectable DMPA, 
30 (14.8%) using an implant, 29 (14%) using oral pills, 6 (3%) using an IUD and 2 (1%) women sterilized. A 
further 9 (3%) women used condoms and one woman (0.3%) used lactational amenorrhea. No reasons were doc-
umented for the 154 women not using contraceptives. In total, 164 women (10 using unreliable and 154 not using 
any method) were not using any reliable contraceptives at baseline. Adjusting for factors indicated in Table 2, 
age and self-reported illicit drug use were independently associated with reliable contraceptives use at baseline. 
Women aged 18–34 years were twice as likely to use a reliable method, adjusted odds ratio (aOR) = 2.07, 95%CI: 
1.21–3.54 compared to those aged 35 years or more. Similarly, self-reported illicit drug users were twice more 
likely to use reliable contraceptives aOR = 2.45, 95%CI: 1.38–4.35 compared to non-illicit drug users (Table 2).
Retention. In total, 294 (84% of 350 expected and 80% of 367 enrolled; FF = 64/71 (90%) and FSW = 230/279 
(82%)) completed all four study visits, up to six months. Overall, 23 (6%) were withdrawn from the study over the 
six months follow up, 11 (3%) due to pregnancy, and 12 (3%) for other reasons (see Fig. 1). Of the 11 women who 
became pregnant, seven (four on injectable and three on oral pills) reported using reliable contraceptive before 
the pregnancy while four were not using any method. The four on injectable had delayed injection by 25, 27, 35 
and 40 days. Of the 367, 357 and 350 women expected at month one, three and six respectively, 94%, 87% and 
84% were seen. The reasons for missing a given visit are indicated in Fig. 1. Compared to those who completed all 
the study follow up visits, those that missed any one visit were younger (mean age, 26.3 vs. 29.7 years), with one 
or no sexual partner 44% vs two or more 29%, new sexual partner 42% vs none 31%, spent up to one year at the 
current location 41% vs more than one year 29%.
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Uptake of reliable contraceptives. The trial promoted reliable contraceptive methods to the 164 women 
(FF = 53 and FSW = 111) not using a reliable method at baseline; of these women 131 (80%; FF = 39 (74%) and 
FSW = 92 (83%)) reported using a reliable contraceptive method during at least one follow up visit. Figure 2 
shows the number of women that used reliable contraceptives at each of the follow up visits, throughout the trial. 
The graph illustrates that 125 (76%) women started using reliable contraceptive in the first month of follow-up 
and 80% used reliable contraceptives at month 6. Overall, 73 (45%) of 164 women used DMPA, and 36 (22%) 
oral pills.
In the 164 women that were eligible for promotion of reliable contraceptives at baseline, age group and report-
ing having sex under the influence of alcohol in the month preceding the interview were independently associated 
with uptake of reliable contraceptives by six months of follow up (in a model adjusted for factors in Table 3). 
Women aged 18–34 years were twice more likely to take up a reliable method, adjusted odds ratio (aOR) = 2.47, 
95%CI: 1.01–6.07 compared to those aged 35 years or more. Those reporting sometimes having sex under influ-
ence of alcohol were less likely to take up a reliable method compared to never (aOR = 0.37, 95%CI: 0.14–0.96, 
Table 3). Though not statistically significant, in this sample, women who had attained some formal education 
were three times (aOR = 3.21, 95%CI: 0.73–14.16) for primary education and four times (aOR = 4.41, 95%CI: 
0.89–21.87) for secondary education more likely to take up a reliable method compared to those without any 
formal education.
Furthermore, 334 (91%; FF = 63/77 (82%) and FSW = 271/290 (93%)) of 367 women enrolled (including the 
203 that were already using a reliable method of contraception at baseline) used a reliable method by the end 
of trial follow up. Of the 334 women that used a reliable method, 197 (59%) used DMPA. Other methods were 
oral pills (n = 60; 18%), implant (n = 31; 9%), IUD (n = 7; 2%), and sterilized (n = 2; 0.6%). Thirty-seven women 
(11%) switched between reliable methods. Of these women, most 19 (51%) switched from DMPA to oral pills. All 
women (131 new reliable contraceptives users and 203 already using at baseline) reported sustained use of a reli-
able method throughout the follow up period. Less than one tenth of women (n = 33; 9%; FF = 14 and FSW = 19) 
did not use any reliable method throughout the study. Of these, seven (FF = 6 and FSW = 1) used condoms and 
26 (FF = 8 and FSW = 18) did not use any form of contraception.
In the 367 women enrolled in the trial, overall factors independently associated with use of reliable contra-
ceptives by six month of follow up included; age group, with women aged 18–34 years being thrice more likely to 
use a reliable method of contraceptives (aOR = 2.86, 95%CI: 1.31–6.24) compared to those aged 35 or more years. 
Other factors included study site [Kampala, aOR = 3.09, 95%CI: 1.36–6.98) compared to Masaka] and education 
(borderline) [secondary or more, aOR = 3.06, 95%CI: 0.78–12.02) compared to no education].
Discussion
We investigated in women of reproductive age in the FF and FSW use of reliable contraceptive methods and asso-
ciated factors at baseline and at the end of a six-month vaccination schedule in two SiVETs. We found that the 
proportion of sexually active women using a reliable method at baseline was low, about one in every two women. 
Promotion and provision of reliable methods by the trial staff increased the proportion of women using a reliable 
method to over 90% at the end of six months of follow up. The baseline use of reliable methods in these popula-
tions was higher than the 35% reported in the general population in Uganda15. It was also higher than 5%-28% 
reported in other HIV prevention trials in West Africa16,17 and East Africa and Southern Africa18. Contrary to 
Figure 1. Study profile of screening, enrolment and follow up of 367 participants in SiVET at Kampala and 
Masaka clinics, Uganda (2012–2017).
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Participant characteristic FF n (%) FSW n (%)
Contraceptive use
uOR (95%CI) LRT-pvalue aOR (95%CI)FF FSW
Overall 77 (100) 290 (100) 24 (31.2) 179 (61.7)
Site <0.001
  Masaka 77 (100) na 24 (31.2) na 1.00 1.00
  Kampala na 290 (100) na 179 (61.7) 3.56 (2.08–6.09) 1.56 (0.66–3.69)
Age group (years) 0.001
  35+ 21 (27.3) 62 (21.4) 5 (23.8) 28 (45.2) 1.00 1.00
  18–34 56 (72.7) 228 (78.6) 19 (33.9) 151 (66.2) 2.26 (1.37–3.72) 2.07 (1.21–3.54)
Tribe 0.107
  Muganda 38 (49.3) 153 (52.8) 12 (31.6) 98 (64.1) 1.00
  Munyankole 7 (9.1) 32 (11.0) 2 (28.6) 19 (59.4) 0.86 (0.43–1.72)
  Munyarwanda 18 (23.4) 20 (6.9) 4 (22.2) 10 (50.0) 0.43 (0.21–0.88)
  Other 14 (18.2) 85 (29.3) 6 (42.9) 52 (61.2) 1.04 (0.64–1.70)
Education 0.183
  None 7 (9.1) 16 (5.5) 3 (42.9) 10 (62.5) 1.0 1.00
  Primary 49 (63.6) 149 (51.4) 14 (28.6) 87 (58.4) 0.80 (0.34–1.91) 0.81 (0.32–2.05)
  Secondary+ 21 (27.3) 125 (43.1) 7 (33.3) 82 (65.6) 1.20 (0.49–2.92) 1.00 (0.38–2.61)
Religion 0.685
  Christian 57 (74.0) 219 (75.5) 20 (35.1) 131 (59.8) 1.00
  Muslim 20 (26.0) 71 (24.5) 4 (20.0) 48 (67.6) 1.10 (0.68–1.78)
Marital status 0.319
  Single, never married 15 (19.5) 68 (23.5) 7 (46.7) 38 (55.9) 1.00
  Married 30 (39.0) 18 (6.2) 11 (36.6) 11 (61.1) 0.71 (0.35–1.46)
  Single, previously married 32 (41.5) 204 (70.3) 6 (18.7) 130 (63.7) 1.15 (0.77–1.82)
Occupation 0.002
  Fishing/related 21 (27.3) 0 (0.0) 5 (23.8) 0 (0.0) 1.00
  Small scale business 27 (35.1) 11 (3.8) 6 (22.2) 9 (81.8) 2.09 (0.63–6.90)
  Hotel/Bar/Saloon 19 (24.6) 111 (38.3) 10 (52.6) 67 (60.4) 4.65 (1.61–13.46)
  Sex work 0 (0.0) 165 (56.9) 0 (0.0) 101 (61.2) 5.05 (1.76–14.46)
  Other 10 (13.0) 3 (1.0) 3 (30.0) 2 (66.7) 2.00 (0.45–8.98)
Duration lived at current location 0.614
  0–1, year 23 (29.9) 51 (15.6) 8 (34.8) 31 (60.8) 1.00
  >one year 54 (70.1) 239 (82.4) 16 (29.6) 148 (61.9) 1.14 (0.68–1.90)
Alcohol consumption (previous one month) 0.099
  None 33 (42.9) 57 (19.7) 11 (33.3) 30 (52.6) 1.00
  Inconsistent 38 (49.3) 147 (50.6) 11 (29.0) 98 (66.7) 1.71 (1.03–2.85)
  Daily 6 (7.8) 86 (29.7) 2 (33.3) 51 (59.3) 1.62 (0.90–2.92)
Sex under alcohol influence (previous one month) 0.222
  Never 45 (58.4) 103 (35.5) 12 (26.7) 63 (61.2) 1.00
  Sometimes 24 (31.2) 169 (58.3) 10 (41.7) 105 (62.1) 1.44 (0.93–2.21)
  Frequently 8 (10.4) 18 (6.2) 2 (25.0) 11 (61.1) 0.97 (0.42–2.24)
Drug use (previous one month) <0.001
  No 71 (92.2) 55 (19.0) 21 (29.6) 24 (43.6) 1.00 1.00
  Yes 6 (7.8) 235 (81.0) 3 (50.0) 155 (66.0) 3.43 (2.18–5.38) 2.45 (1.38–4.35)
Genital discharge (previous 3 months) 0.055
  Yes 51 (55.2) 88 (30.3) 14 (27.4) 54 (61.4) 1.00
  No 26 (33.8) 202 (69.7) 10 (38.5) 125 (61.9) 1.52 (0.99–2.31)
Genital sores/ulcer disease (previous 3 months) 0.009
  Yes 40 (52.0) 48 (16.6) 11 (27.5) 27 (56.3) 1.00
  No 37 (48.0) 242 (83.4) 13 (35.1) 152 (62.8) 1.90 (1.17–3.09)
Number of sexual partners (previous 3 months) <0.001
  0/1 47 (61.0) 3 (1.0) 13 (27.7) 2 (66.7) 1.00 1.00
  2+ 30 (39.0) 287 (99.0) 11 (36.7) 177 (61.7) 3.40 (1.78–6.48) 1.30 (0.52–3.29)
New sexual partner (previous 3 months) 0.758
  No 0 (0.0) 24 (8.3) 0 (0.0) 14 (58.3) 1.00
  Yes 77 (100) 266 (91.7) 24 (31.2) 165 (62.0) 0.88 (0.38–2.03)
Continued
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these HIV prevention trials, women enrolled into SiVET were selected based on willingness to delay pregnancy 
through use of a reliable method of contraceptive during the vaccination period. In SiVET, the majority of women 
reporting reliable contraceptive use at baseline and at the end of vaccination used injectable DMPA, which is con-
sistent with both national data15 and data from concluded HIV prevention trials12,23 in Uganda.
At baseline, reliable contraceptive use differed significantly by age group and self-reported illicit drug use. 
Nationally age15 has been associated with contraceptive use. This is also consistent with previous studies in East 
and Southern Africa18 that reported association of effective contraceptives use with age. Contrary to previous 
studies33,34 that showed high contraceptives use among non-drug users, we found a twofold higher use of reliable 
contraceptives among illicit drug users. Women involved in sex work dominated the SiVET protocol and these 
have been linked to high illicit drug35 and contraceptives use36. It is likely that the perceived risk of pregnancy in 
this category of women is higher than that of the general population and could influence practices.
About half of the women were not using reliable contraceptive methods at baseline but majority started using 
them mainly within the first month of follow up. By six months, nine in every ten women were using a reliable 
method of contraceptives. Uptake of reliable contraceptives in women that were not using such methods at base-
line was independently associated with age group, education (borderline) and self-reported having had sex under 
alcohol influence. Similarly, older age and lower educational status are associated with lower contraceptive use 
nationally15. Women that reported sometimes or frequently having sex under influence of alcohol were less likely 
to use reliable contraceptives. Alcohol use has been linked to impaired decision making in complex situations37.
Though women switched between contraceptive methods, it was encouraging that the switches were within 
reliable methods and women sustained use of these methods throughout follow up. Uptake and sustained use 
coupled with higher baseline use of reliable methods than that in the general population could have played a 
role in the relatively lower proportion of pregnancy than that observed in other HIV prevention trials20. Seven 
women got pregnant while using reliable contraceptives in the trial. The four women on injectable DMPA had 
all delayed an injection by about one month perhaps indicating they were unaware of the need to renew on time. 
Three women were using oral pills and adherence issues with use of oral pills have been well-documented11. In an 
actual HIV vaccine efficacy trial, these women would have to be withdrawn from the trial. Encouraging women 
Participant characteristic FF n (%) FSW n (%)
Contraceptive use
uOR (95%CI) LRT-pvalue aOR (95%CI)FF FSW
Condom use with the new sexual partner 0.001
  Never 47 (61.0) 9 (3.4) 15 (31.9) 6 (66.7) 1.00
  Sometimes 19 (24.7) 50 (18.8) 6 (31.6) 26 (52.0) 1.44 (0.70–2.96)
  Always 11 (14.3) 207 (77.8) 3 (27.3) 133 (64.3) 2.76 (1.51–5.07)
Away from home ≥3 days/week 0.741
  Yes 24 (31.2) 98 (33.8) 6 (25.0) 60 (61.2) 1.00
  No 53 (68.8) 192 (66.2) 18 (34.0) 119 (62.0) 1.08 (0.70–1.67)
Table 2. Participant baseline characteristics, proportion and factors associated with using reliable 
contraceptives among 367 participants enrolled in SiVET in Uganda (2012–2017). uOR-Unadjusted odds ratio, 
aOR-Adjusted odds ratio, CI-Confidence interval, %-percent, na-Not applicable, LRT = likelihood ratio test. 
FF-Fisherfolk, FSW-Female sex workers.
Figure 2. Reliable contraceptives use overall and uptake by the 164 women that were not using a reliable 
method at enrolment into SiVET, Uganda (2012–2017).
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Participant 
characteristic FF n (%)
Uptake
FSW n(%) uOR (95%CI) LRT p-value aOR (95%CI)FF FSW
Overall 53 (100) 111 (100) 39 (73.6) 92 (82.9) na na na
Site
   Masaka 53 (100) na 39 (73.6) na 1.00 0.172 1.00
   Kampala na 111 (100) na 92 (82.9) 1.74 (0.79–3.81) 1.37 (0.50–3.73)
Age group (years)
   35+ 16 (30.2) 34 (30.6) 8 (50.0) 27 (79.4) 1.00 0.041 1.00
   18–34 37 (69.8) 77 (69.4) 31 (83.8) 65 (84.4) 2.29 (1.04–5.02) 2.47 (1.01–6.07)
Tribe
   Muganda 26 (49.1) 55 (49.6) 22 (84.6) 44 (80.0) 1.00 0.120
   Munyankole 5 (9.4) 13 (11.7) 3 (60.0) 11 (84.6) 0.80 (0.23–2.76)
   Munyarwanda 14 (26.4) 10 (9.0) 7 (50.0) 8 (80.0) 0.38 (0.14–1.03)
   Other 8 (15.1) 33 (29.7) 7 (87.5) 29 (87.9) 1.64 (0.55–4.87)
Education
   None 4 (7.6) 6 (5.4) 2 (50.0) 4 (66.7) 1.00 0.086 1.00
   Primary 35 (66.0) 62 (55.9) 25 (71.4) 50 (80.7) 2.27 (0.59–8.78) 3.21 (0.73–14.16)
   Secondary+ 14 (26.4) 43 (38.7) 12 (85.7) 38 (88.4) 4.76 (1.07–21.17) 4.41 (0.89–21.87)
Religion
   Christian 37 (69.8) 88 (79.3) 27 (73.0) 73 (83.0) 1.00 0.945
   Muslim 16 (30.2) 23 (20.7) 12 (75.0) 19 (82.6) 0.97 (0.40–2.36)
Marital status
   Single never 
married 8 (15.1) 30 (27.0) 7 (87.5) 25 (83.3) 1.00 0.156 1.00
   Married 19 (35.8) 7 (6.3) 12 (63.2) 5 (71.4) 0.35 (0.11–1.16) 0.39 (0.10–1.62)
   Single ever 
married 26 (49.1) 74 (66.7) 20 (76.9) 62 (83.8) 0.85 (0.31–2.35) 1.08 (0.35–3.39)
Occupation
   Fishing/related 16 (30.2) 0 (0.0) 11 (68.8) 0 (0.0) 1.00 0.223
   Small scale 
business 21 (39.6) 2 (1.8) 17 (81.0) 2 (100) 2.16 (0.48–9.77)
   Hotel/Bar/Saloon 9 (17.0) 44 (39.6) 7 (77.8) 33 (75.0) 1.40 (0.41–4.78)
   Sex work 0 (0.0) 64 (57.7) 0 (0.0) 56 (87.5) 3.18 (0.88–11.57)
   Other 7 (13.2) 1 (0.9) 4 (57.1) 1 (100) 0.76 (0.13–4.49)
Duration lived at current location
  0–1, year 15 (28.3) 20 (18.0) 13 (86.7) 15 (75) 1.00 0.984
   >one year 38 (71.7) 91 (82.0) 26 (68.4) 77 (84.6) 0.99 (0.39–2.52)
Alcohol consumption (previous one month)
   Non 22 (41.5) 27 (24.3) 17 (77.3) 23 (85.2) 1.00 0.173
   Inconsistent 27 (50.9) 49 (44.1) 21 (77.8) 43 (87.8) 1.20 (0.46–3.10)
   Daily 4 (7.6) 35 (31.6) 1 (25.0) 26 (74.3) 0.51 (0.19–1.37)
Sex under alcohol influence (previous one month)
   Never 33 (62.3) 40 (36.0) 26 (78.8) 36 (90.0) 1.00 0.343 1.00
   Sometimes 14 (26.4) 64 (57.7) 10 (71.4) 49 (76.6) 0.55 (0.24–1.26) 0.37 (0.14–0.96)
   Frequently 6 (11.3) 7 (6.3) 3 (50.0) 7 (100) 0.59 (0.14–2.50) 0.70 (0.15–3.34)
Drug use (previous one month)
   No 50 (94.3) 31 (27.9) 36 (72.0) 26 (83.9) 1.00 0.292
   Yes 3 (5.7) 80 (72.1) 3 (100) 66 (82.5) 1.51 (0.70–3.26)
Genital discharge (previous 3 months)
   Yes 37 (69.8) 34 (30.6) 27 (73.0) 26 (76.5) 1.00 0.146
   No 16 (30.2) 77 (69.4) 12 (75.0) 66 (85.7) 1.77 (0.82–3.81)
Genital sores/ulcer disease (previous 3 months)
   Yes 29 (54.7) 21 (18.9) 21 (72.4) 15 (71.4) 1.00 0.103 1.00
   No 24 (45.3) 90 (81.1) 18 (75.0) 77 (85.6) 1.94 (0.88–4.28) 1.92 (0.78–4.73)
Number of sexual partners (previous 3 months)
   0/1 34 (64.2) 1 (0.9) 26 (76.5) 1 (100) 1.00 0.653
   2+ 19 (35.8) 110 (99.1) 13 (68.4) 91 (82.7) 1.23 (0.50–3.04)
New sexual partner (previous 3 months)
   No 0 (0.0) 10 (9.0) 0 (0.0) 9 (90.0) 1.00 0.374
Continued
8Scientific RepoRtS |         (2019) 9:15418  | https://doi.org/10.1038/s41598-019-51879-2
www.nature.com/scientificreportswww.nature.com/scientificreports/
to receive their contraception injection or take their pills on time through phone calls and/or home visits would 
improve adherence.
The retention in SiVET was higher than the average (75%) reported in observational cohorts7,29,30 in these pop-
ulations. High retention in the trial setting is likely a result of the rigorous participant tracking system employed 
compared to observational cohorts. Though it took about three months for 5% of the new reliable contraceptive 
users to get on reliable contraceptives, most had done so within a month of enrolment. In these key populations, 
it may not be necessary to put women on reliable contraceptives for atleast three months before screening for trial 
enrolment instead these could happen concurrently. The high retention coupled with high screening-enrolment 
ratio and high use of reliable contraceptives make women in these key populations attractive to enroll in the 
future HIV vaccine efficacy and other HIV prevention trials.
A limitation of our trial is that we did not collect data on the reasons for not using reliable or any contracep-
tives. Furthermore, we did not collect data on reasons for switching between reliable methods. Such reasons 
would have been instrumental in informing modification of messages on contraceptives use in HIV prevention 
trials in these key populations. Even though the trials (in FF and FSW) were similar, two different study teams 
with a somewhat different protocol conducted them. Differences in correlates of reliable contraceptive use may 
exist by site, but the small sample size prevented site stratification. However, other than occupation and illicit drug 
use, most of the women characteristics in the two populations were comparable.
The major strength of our trial is that we promoted and provided reliable contraceptives in the context of HIV 
vaccine efficacy trial, counselled women on the importance of reliable contraceptives use and provided them with 
a method of their choice.
conclusion
In this SiVET, the proportion of women using reliable contraceptives improved from one in every two women 
at baseline to nine in every 10 women at the end of follow up. The use of reliable methods at baseline was par-
ticularly higher among young women and illicit drug users. Promotion and provision of reliable contraceptives 
to women not using them at baseline improved the proportion using them within the first month of follow up. 
Uptake of reliable contraceptives increased with increasing education and decreased with increasing age and the 
frequency of having sex under alcohol influence. All women using reliable methods continued to use them (or 
another reliable method) throughout follow-up. The sustained use highlights the importance of promoting and 
providing reliable contraceptives to trial participants in populations where pregnancy could lead to discontinua-
tion of the use of investigational product. We observed a lower proportion of women becoming pregnant during 
the trial follow up than that reported in the concluded HIV prevention trials in the region. This trial could have 
filled the unmet need for reliable contraceptives in these populations in term of promotion and provision as well 
as enhancing accurate contraceptive messaging. It is particularly encouraging that concurrent vaccination and 
provision of contraceptives was possible in these populations making them good candidates for future HIV vac-
cine efficacy and other prevention trials.
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Participant 
characteristic FF n (%)
Uptake
FSW n(%) uOR (95%CI) LRT p-value aOR (95%CI)FF FSW
   Yes 53 (100) 101 (91.0) 39 (73.6) 83 (82.2) 0.42 (0.05–3.47)
Condom use with the new sexual partner
   Never 32 (60.4) 3 (3.0) 24 (75.0) 3 (100) 1.00 0.721
   Inconsistently 13 (24.5) 24 (23.7) 9 (69.2) 22 (91.7) 1.53 (0.47–5.00)
   Always 8 (15.1) 74 (73.3) 6 (75.0) 58 (78.4) 1.00 (0.39–2.56)
Away from home ≥3 days/week
   Yes 18 (34.0) 38 (34.2) 16 (88.9) 29 (76.3) 1.00 0.912
   No 35 (66.0) 73 (65.8) 23 (65.7) 63 (86.3) 0.96 (0.43–2.15)
Table 3. Proportion and factors associated with uptake of reliable contraceptives among 164 women that were 
not using reliable methods at enrolled into SiVET in Uganda (2012–2017). uOR-Unadjusted odds ratio, aOR-
Adjusted odds ratio, CI-Confidence interval, %-percent, na-Not applicable, FF-Fisherfolk, FSW-Female sex 
workers.
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